AxoGen, Inc. Appoints Jon Gingrich Chief Commercial Officer

World News: . []

ALACHUA, Fla., July 17, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jon S. Gingrich to the newly created role of Chief Commercial Officer. Gingrich brings more than 20 years of global medical device and health care sales, marketing, and general management experience to AxoGen. As a member of the AxoGen executive leadership team, Gingrich will report directly to Karen Zaderej, President and CEO, and will oversee the development and execution of the company’s sales and marketing strategies.

“AxoGen is creating a new platform of nerve repair by providing surgeons with clinically relevant solutions across a wide spectrum of nerve injuries and conditions,” commented Zaderej. “Jon’s extensive medical device experience strengthens our commercial leadership and will help us drive penetration of our existing markets, expand into new applications, introduce new products, and build global markets.”

Gingrich most recently served in senior general management and commercial roles at Hologic Inc., including Global Vice President and General Manager, Skeletal Health Solutions and Group Global Vice President, Marketing, Breast and Skeletal Health Solutions. Prior to Hologic, he spent 15 years with Boston Scientific, holding several commercial and international positions of increasing responsibility, including General Manager, Cardiac Rhythm Management of Japan, and most recently as Vice President International Commercialization, Cardiac Rhythm Management.   

“AxoGen’s life-changing technology is reshaping the peripheral nerve repair industry and I am excited to help lead the organization through its next stage of growth,” commented Gingrich. “The company is uniquely positioned to bring significant value to patients, surgeons, health care providers, and payers on a global scale as it advances the science and practice of nerve repair.”

AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal™ Neurosensory & Motor Testing System and AxoTouch™ Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

AxoGen Corporation
Annette Ruzicka, Corporate & Investor Communications

The Trout Group – Investor Relations
Brian Korb

More news and information about AxoGen, Inc.

Published By:

Globe Newswire: 12:00 GMT Monday 17th July 2017

Published: .

Search for other references to "axogen" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers